Isosorbide mononitrate

Isosorbide mononitrate

Clinical data
AHFS/Drugs.com	Consumer Drug Information
Pregnancy category	C (USA)
Routes of administration	oral
ATC code	C01DA14 (WHO)
Pharmacokinetic data
Bioavailability	>95%
Protein binding	<5%
Metabolism	Hepatic
Elimination half-life	5 hours
Excretion	Renal (93%)
Identifiers
IUPAC name 8-nitrooxy-2,6-dioxabicyclo[3.3.0]octan-4-ol
CAS Number	16051-77-7 Y
PubChem CID	27661
IUPHAR/BPS	7052
DrugBank	DB01020 Y
ChemSpider	25736 Y
UNII	LX1OH63030
KEGG	D00630 Y
ChEBI	CHEBI:6062 Y
ChEMBL	ChEMBL1311 Y
CompTox Dashboard (EPA)	DTXSID9023176
ECHA InfoCard	100.036.527
Chemical and physical data
Formula	C6H9NO6
Molar mass	191.139 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES [O-][N+](=O)O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1
InChI InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1 Y Key:YWXYYJSYQOXTPL-SLPGGIOYSA-N Y
(verify)

Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold in the USA by Kremers Urban under the trade name Monoket, also sold in the USA under the name Imdur, and marketed in the UK under the trade names: Monosorb, Chemydur. In India, this drug is available under the brand names of Ismo, Isonorm, Monotrate, Solotrate, and Monit. In Russia it is occasionally used under the brand names Monocinque and Pektrol.

Uses

Isosorbide mononitrate is a nitrate-class drug used for the prophylactic treatment of angina pectoris; that is, it is taken in order to prevent or at least reduce the occurrence of angina. Research on isosorbide mononitrate as a cervical ripener to reduce time at hospital to birth is supportive.

Side-effects

The adverse reactions, which follow, have been reported in studies with isosorbide mononitrate:

Very common: Headache predominates (up to 30%) necessitating withdrawal of 2 to 3% of patients, but the incidence reduces rapidly as treatment continues .

Common: Tiredness, sleep disturbances (6%) and gastrointestinal disturbances (6%) have been reported during clinical trials with isosorbide mononitrate modified-release tablets, but at a frequency no greater than for placebo. Hypotension (4 to 5%), poor appetite (2.5%), nausea (1%).

Adverse effects associated with the clinical use of the drug are as expected with all nitrate preparations. They occur mainly in the early stages of treatment.

Hypotension (4%) with symptoms such as dizziness and nausea (1%) have been reported. In general, these symptoms disappear during long-term treatment.

Other reactions that have been reported with isosorbide mononitrate modified-release tablets include tachycardia, vomiting, diarrhoea, vertigo, and heartburn.

Interactions

• Sildenafil (Viagra). Concomitant administration of isosorbide mononitrate and sildenafil (Viagra) or other phosphodiesterase inhibitors (Tadalafil and Udenafil) can potentiate the vasodilatory effect of isosorbide mononitrate with the potential result of serious side-effects such as syncope or myocardial infarction. Life-threatening hypotension may also occur. Therefore, sildenafil should not be given to patients already receiving isosorbide mononitrate therapy.
• Sulfhydryl-containing compounds. The metabolism of organic nitrates to nitric oxide is dependent on the presence of sulfhydryl groups in the muscle. The combination of oral N-acetylcysteine and a single dose of sustained-release isosorbide mononitrate 60 mg significantly prolonged the total exercise time in patients with angina pectoris and angiographically proven significant coronary artery disease, when compared with isosorbide mononitrate alone. Concomitant administration of other exogenous sources of sulfhydryl groups such as methionine and captopril may produce a similar interaction.
• Phenylalkylamine calcium antagonists. The addition of a calcium channel blocker of the verapamil type, such as gallopamil 75 mg, has been shown to further improve left ventricular functional parameters when given in combination with isosorbide mononitrate in a sustained-release formulation.
• Propranolol. The addition of isosorbide mononitrate to propranolol treatment in patients with cirrhosis and portal hypertension caused a marked fall in portal pressure, a reduction in hepatic blood flow, cardiac output and mean arterial blood pressure, but no additional change in azygos blood flow. The additional effect of isosorbide mononitrate was especially evident in patients whose portal pressure was not reduced by propranolol.
• Calcium antagonists (general). Marked symptomatic orthostatic hypotension has been reported when calcium antagonists and organic nitrates were used in combination. Dose adjustments of either class of agent may be necessary.

External links

• . GPnotebook https://www.gpnotebook.co.uk/simplepage.cfm?ID=1516961817. {{cite web}}: Missing or empty |title= (help)